O
Orum Therapeutics Inc
KOSDAQ:475830
Orum Therapeutics Inc
KOSDAQ:475830
Price:
117 500
KRW
11.59%
Market Closed
Market Cap:
₩2.5T
Orum Therapeutics Inc
Research & Development
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Orum Therapeutics Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Orum Therapeutics Inc
KOSDAQ:475830
|
Research & Development
-₩17B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Research & Development
-₩218.9B
|
CAGR 3-Years
-91%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Research & Development
-₩20.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Research & Development
-₩17.9B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Research & Development
-₩28.4B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-31%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Research & Development
-₩95.6B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
No Stocks Found
Orum Therapeutics Inc
Glance View
Orum Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2025-02-14. The firm is principally engaged in the research and development of new biopharmaceuticals for cancer and immune diseases based on its platforms.
Intrinsic Value
800.61
KRW
Overvaluation 99%
O
See Also
What is Orum Therapeutics Inc's Research & Development?
Research & Development
-17B
KRW
-17B
KRW
Based on the financial report for Dec 31, 2024, Orum Therapeutics Inc's Research & Development amounts to -17B KRW.
What is Orum Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 1Y
9%
9%
Over the last year, the Research & Development growth was 9%.
